Similarly, decreased levels of CXCL12 in BM plasma samples from a cohort of patients with active multiple myeloma as compared with a premalignant stage support the hypothesis of a reduced NK cell surveillance based on reduced BM recruitment (39). This evidence concerns the gene CXCL12 and plasma cell myeloma.